HCC
Latest News
Latest Videos
CME Content
More News
Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the current treatment landscape for liver cancer and the advances seen over the last decade at the 2018 International Liver Cancer Association Annual Conference.
Strong efficacy signals and a tolerable safety profile were observed with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma, according to preliminary findings presented at the 2018 International Liver Cancer Association Annual Conference.
According to a presentation during the 2018 International Liver Cancer Association Annual Conference, the rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded systemic treatment options over the last 2 years. This has created a need for new sequencing strategies in HCC.
Fabio Piscaglia, MD, discusses the updated 2018 European Association for the Study of the Liver clinical guidelines, which were presented during the 12th International Liver Cancer Association Annual Conference in London, United Kingdom.
In an interview with <em>Targeted Oncology</em>, Abou-Alfa discussed those clinical trials and other investigated treatment options for patients with hepatocellular carcinoma. He also highlighted his hopes for the future of this disease.
<div>The combination of the MEK inhibitor refametinib and sorafenib improved overall survival and overall response rate compared with refametinib alone in patients with <em>RAS</em>-mutated hepatocellular carcinoma, according to an analysis of a pair of phase II proof-of-concept studies.</div>
Lenvatinib (Lenvima) has been approved by the European Commission as a first-line treatment for adults with advanced or unresectable hepatocellular carcinoma, based on data from the phase III REFLECT trial.
Lenvatinib (Lenvima) has been granted approval by the FDA as a first-line treatment for patients with unresectable hepatocellular carcinoma, based on data from the phase III REFLECT trial.
Compared with sorafenib (Nexavar) alone, sorafenib in combination with selective internal radiation therapy did not provide a significant survival improvement for patients with advanced hepatocellular carcinoma, according to results from the palliative cohort of the SORAMIC trial presented at the 2018 World Congress on Gastrointestinal Cancer in Barcelona, Spain. However, overall survival improvements were seen with the combination in select subgroup analyses.
The FDA issued several approvals in July, including in colorectal cancer, breast cancer, prostate cancer, and acute myeloid leukemia. Here’s a look back on the FDA happenings for the month of July 2018.
Atezolizumab (Tecentriq) has been granted a breakthrough therapy designation by the FDA for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.
<em>Targeted Oncology</em>, a print and digital resource that offers content and expert opinions on precision medicine in oncology, becomes partners with the International Liver Cancer Association, announced Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of <em>Targeted Oncology.</em>
Richard Kim, MD, recently shared his treatment considerations and decisions he makes when treating patients with hepatocellular carcinoma and colorectal cancer. Kim explained his treatment decisions based on 2 gastrointestinal case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives program.
The PD-1 inhibitor pembrolizumab (Keytruda) has been granted a priority review designation by the FDA for use in previously treated patients with advanced hepatocellular carcinoma, according to Merck, the manufacturer of the agent.
